A biotech startup breaks a 3-year silence, displaying a $65M raise and a next-gen approach to PARP
Victoria Richon’s team at Ribon Therapeutics has been cruising under the biotech radar for the past 3 years. But with a $65 million B round …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
